The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Vaccine (Include COVID-19) Market Research Report 2024
Synopsis
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Global Vaccine (Include COVID-19) market is projected to reach US$ 71990 million in 2029, increasing from US$ 140120 million in 2022, with the CAGR of 3.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Vaccine (Include COVID-19) market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Vaccine (Include COVID-19) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
KM Biologics
Pfizer
Merck
Sinovac
Zhejiang Pukang
Walvax Biotechnology
Bharat Biotech
Serum Institute
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
LG Life Sciences
Segment by Type
Inactivated Vaccine
Attenuated Vaccine
mRNA
Other
Segment by Application
Public
Private
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Vaccine (Include COVID-19) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Global Vaccine (Include COVID-19) market is projected to reach US$ 71990 million in 2029, increasing from US$ 140120 million in 2022, with the CAGR of 3.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Vaccine (Include COVID-19) market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Vaccine (Include COVID-19) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
KM Biologics
Pfizer
Merck
Sinovac
Zhejiang Pukang
Walvax Biotechnology
Bharat Biotech
Serum Institute
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
LG Life Sciences
Segment by Type
Inactivated Vaccine
Attenuated Vaccine
mRNA
Other
Segment by Application
Public
Private
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Vaccine (Include COVID-19) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Vaccine (Include COVID-19) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Inactivated Vaccine
1.2.3 Attenuated Vaccine
1.2.4 mRNA
1.2.5 Other
1.3 Market by Application
1.3.1 Global Vaccine (Include COVID-19) Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Public
1.3.3 Private
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Vaccine (Include COVID-19) Market Perspective (2018-2029)
2.2 Vaccine (Include COVID-19) Growth Trends by Region
2.2.1 Global Vaccine (Include COVID-19) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Vaccine (Include COVID-19) Historic Market Size by Region (2018-2023)
2.2.3 Vaccine (Include COVID-19) Forecasted Market Size by Region (2024-2029)
2.3 Vaccine (Include COVID-19) Market Dynamics
2.3.1 Vaccine (Include COVID-19) Industry Trends
2.3.2 Vaccine (Include COVID-19) Market Drivers
2.3.3 Vaccine (Include COVID-19) Market Challenges
2.3.4 Vaccine (Include COVID-19) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Vaccine (Include COVID-19) Players by Revenue
3.1.1 Global Top Vaccine (Include COVID-19) Players by Revenue (2018-2023)
3.1.2 Global Vaccine (Include COVID-19) Revenue Market Share by Players (2018-2023)
3.2 Global Vaccine (Include COVID-19) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Vaccine (Include COVID-19) Revenue
3.4 Global Vaccine (Include COVID-19) Market Concentration Ratio
3.4.1 Global Vaccine (Include COVID-19) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Vaccine (Include COVID-19) Revenue in 2022
3.5 Vaccine (Include COVID-19) Key Players Head office and Area Served
3.6 Key Players Vaccine (Include COVID-19) Product Solution and Service
3.7 Date of Enter into Vaccine (Include COVID-19) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Vaccine (Include COVID-19) Breakdown Data by Type
4.1 Global Vaccine (Include COVID-19) Historic Market Size by Type (2018-2023)
4.2 Global Vaccine (Include COVID-19) Forecasted Market Size by Type (2024-2029)
5 Vaccine (Include COVID-19) Breakdown Data by Application
5.1 Global Vaccine (Include COVID-19) Historic Market Size by Application (2018-2023)
5.2 Global Vaccine (Include COVID-19) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Vaccine (Include COVID-19) Market Size (2018-2029)
6.2 North America Vaccine (Include COVID-19) Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Vaccine (Include COVID-19) Market Size by Country (2018-2023)
6.4 North America Vaccine (Include COVID-19) Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Vaccine (Include COVID-19) Market Size (2018-2029)
7.2 Europe Vaccine (Include COVID-19) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Vaccine (Include COVID-19) Market Size by Country (2018-2023)
7.4 Europe Vaccine (Include COVID-19) Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Vaccine (Include COVID-19) Market Size (2018-2029)
8.2 Asia-Pacific Vaccine (Include COVID-19) Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Vaccine (Include COVID-19) Market Size by Region (2018-2023)
8.4 Asia-Pacific Vaccine (Include COVID-19) Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Vaccine (Include COVID-19) Market Size (2018-2029)
9.2 Latin America Vaccine (Include COVID-19) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Vaccine (Include COVID-19) Market Size by Country (2018-2023)
9.4 Latin America Vaccine (Include COVID-19) Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Vaccine (Include COVID-19) Market Size (2018-2029)
10.2 Middle East & Africa Vaccine (Include COVID-19) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Vaccine (Include COVID-19) Market Size by Country (2018-2023)
10.4 Middle East & Africa Vaccine (Include COVID-19) Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Vaccine (Include COVID-19) Introduction
11.1.4 Sanofi Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 CSL
11.2.1 CSL Company Detail
11.2.2 CSL Business Overview
11.2.3 CSL Vaccine (Include COVID-19) Introduction
11.2.4 CSL Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.2.5 CSL Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Vaccine (Include COVID-19) Introduction
11.3.4 GSK Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.3.5 GSK Recent Development
11.4 Viatris
11.4.1 Viatris Company Detail
11.4.2 Viatris Business Overview
11.4.3 Viatris Vaccine (Include COVID-19) Introduction
11.4.4 Viatris Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.4.5 Viatris Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Vaccine (Include COVID-19) Introduction
11.5.4 AstraZeneca Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Hualan Bio
11.6.1 Hualan Bio Company Detail
11.6.2 Hualan Bio Business Overview
11.6.3 Hualan Bio Vaccine (Include COVID-19) Introduction
11.6.4 Hualan Bio Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.6.5 Hualan Bio Recent Development
11.7 Changchun Institute of Biological
11.7.1 Changchun Institute of Biological Company Detail
11.7.2 Changchun Institute of Biological Business Overview
11.7.3 Changchun Institute of Biological Vaccine (Include COVID-19) Introduction
11.7.4 Changchun Institute of Biological Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.7.5 Changchun Institute of Biological Recent Development
11.8 Sinovac
11.8.1 Sinovac Company Detail
11.8.2 Sinovac Business Overview
11.8.3 Sinovac Vaccine (Include COVID-19) Introduction
11.8.4 Sinovac Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.8.5 Sinovac Recent Development
11.9 KM Biologics
11.9.1 KM Biologics Company Detail
11.9.2 KM Biologics Business Overview
11.9.3 KM Biologics Vaccine (Include COVID-19) Introduction
11.9.4 KM Biologics Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.9.5 KM Biologics Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Vaccine (Include COVID-19) Introduction
11.10.4 Pfizer Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.10.5 Pfizer Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Vaccine (Include COVID-19) Introduction
11.11.4 Merck Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.11.5 Merck Recent Development
11.12 Sinovac
11.12.1 Sinovac Company Detail
11.12.2 Sinovac Business Overview
11.12.3 Sinovac Vaccine (Include COVID-19) Introduction
11.12.4 Sinovac Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.12.5 Sinovac Recent Development
11.13 Zhejiang Pukang
11.13.1 Zhejiang Pukang Company Detail
11.13.2 Zhejiang Pukang Business Overview
11.13.3 Zhejiang Pukang Vaccine (Include COVID-19) Introduction
11.13.4 Zhejiang Pukang Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.13.5 Zhejiang Pukang Recent Development
11.14 Walvax Biotechnology
11.14.1 Walvax Biotechnology Company Detail
11.14.2 Walvax Biotechnology Business Overview
11.14.3 Walvax Biotechnology Vaccine (Include COVID-19) Introduction
11.14.4 Walvax Biotechnology Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.14.5 Walvax Biotechnology Recent Development
11.15 Bharat Biotech
11.15.1 Bharat Biotech Company Detail
11.15.2 Bharat Biotech Business Overview
11.15.3 Bharat Biotech Vaccine (Include COVID-19) Introduction
11.15.4 Bharat Biotech Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.15.5 Bharat Biotech Recent Development
11.16 Serum Institute
11.16.1 Serum Institute Company Detail
11.16.2 Serum Institute Business Overview
11.16.3 Serum Institute Vaccine (Include COVID-19) Introduction
11.16.4 Serum Institute Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.16.5 Serum Institute Recent Development
11.17 Panacea Biotec Ltd
11.17.1 Panacea Biotec Ltd Company Detail
11.17.2 Panacea Biotec Ltd Business Overview
11.17.3 Panacea Biotec Ltd Vaccine (Include COVID-19) Introduction
11.17.4 Panacea Biotec Ltd Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.17.5 Panacea Biotec Ltd Recent Development
11.18 Bio-Med
11.18.1 Bio-Med Company Detail
11.18.2 Bio-Med Business Overview
11.18.3 Bio-Med Vaccine (Include COVID-19) Introduction
11.18.4 Bio-Med Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.18.5 Bio-Med Recent Development
11.19 Halfkin Bio-Pharmaceuticals
11.19.1 Halfkin Bio-Pharmaceuticals Company Detail
11.19.2 Halfkin Bio-Pharmaceuticals Business Overview
11.19.3 Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Introduction
11.19.4 Halfkin Bio-Pharmaceuticals Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.19.5 Halfkin Bio-Pharmaceuticals Recent Development
11.20 LG Life Sciences
11.20.1 LG Life Sciences Company Detail
11.20.2 LG Life Sciences Business Overview
11.20.3 LG Life Sciences Vaccine (Include COVID-19) Introduction
11.20.4 LG Life Sciences Revenue in Vaccine (Include COVID-19) Business (2018-2023)
11.20.5 LG Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
